iTaf9-11

General#

Cell Line

hPSCreg Name ICAGi001-A
Alternative name(s)
iTaf9-11
Cell line type Human induced pluripotent stem cell (hiPSC)
Last update 22nd May 2019
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator THE FEDERAL RESEARCH CENTER INSTITUTE OF CYTOLOGY AND GENETICS (ICAG)
Owner THE FEDERAL RESEARCH CENTER INSTITUTE OF CYTOLOGY AND GENETICS (ICAG)
Distributors
Derivation country Russia

External Databases

BioSamples SAMEA5230331
Cellosaurus CVCL_UF64

General Information

Publications
* Is the cell line readily obtainable for third parties?
Yes
Research: allowed
Clinical: not allowed
Commercial: not allowed

Donor Information#

General Donor Information

Sex female
Ethnicity Caucasian

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
Mental retardation, autosomal dominant 39; MRD39; OMIM 616521 (chromosome 2p25.3 deletion syndrome)
The donor is a carrier of a disease-associated mutation and affected.
Family history de novo
Is the medical history available upon request? yes, Research Institute of Medical Genetics, TNMRC
Is clinical information available? yes, Research Institute of Medical Genetics, TNMRC

Karyotyping (Donor)

Has the donor karyotype been analysed?
Yes
arr[GRCh38] 2p25.3(42444_2684871)x1 dn, 2p25.3-p23.3(2771354_24258056)x3 dn
Karyotyping method: Array CGH

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA5230332

Ethics#

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold a copy of the SIGNED Donor Consent Form? Yes
Alternatives to consent
Has the donor agreed to be re-contacted? Unknown
Has the donor been informed about how her/his data will be protected? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
Policy for access to genetic information Controlled Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? The study was approved by the Scientific Ethics Committee of Research Institute of Medical Genetics, Tomsk NRMC
Approval number protocol number 106/2017
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? The study was approved by the Scientific Ethics Committee of Research Institute of Medical Genetics, Tomsk NRMC
Approval number protocol number 106/2017
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation#

General

Source cell type
skin fibroblast
Passage number reprogrammed 5

Reprogramming method

Vector type Integrating
Vector Virus (Lentivirus)
Genes
Is the used vector excisable?
No
Absence of reprogramming vector(s)?
No
Reprogramming vectors silenced?
Unknown
Vector map

Vector free reprogramming

Other

Selection criteria for clones morphology marker expression
Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions#

Surface coating Gelatin
Feeder cells mouse embryonic fibroblasts
Cellfinder Ont Id: EFO_0004040
Passage method Mechanically
CO2 Concentration 5 %
Medium Other medium:
Base medium: DMEM/F12
Main protein source: Knock-out serum replacement
Serum concentration: 20 %
Supplements
bFGF 10 µg/ml
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation#

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR FACS Enzymatic Assay Expression Profiles
NANOG
Yes
POU5F1 (OCT-4)
Yes
TRA 1-60
Yes
SSEA-3
Yes
Score:
Marker Present Absent
mCpG
OCT4
Morphology pictures
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro spontaneous differentiation
Marker Expressed
AFP
Yes
SOX17
Yes
Morphology
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
Marker Expressed
MSX1
Yes
FLK1
Yes
Morphology
Ectoderm
Ont Id: UBERON_0000924
In vitro spontaneous differentiation
Marker Expressed
MAP2
Yes
Morphology

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46,XX,der (2)
Karyotyping method: G-Banding

Other Genotyping (Cell Line)